(NASDAQ: APRE) Aprea Therapeutics's forecast annual revenue growth rate of 0.95% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Aprea Therapeutics's revenue in 2024 is $583,231.On average, 1 Wall Street analysts forecast APRE's revenue for 2024 to be $3,258,129, with the lowest APRE revenue forecast at $3,258,129, and the highest APRE revenue forecast at $3,258,129. On average, 1 Wall Street analysts forecast APRE's revenue for 2025 to be $3,258,129, with the lowest APRE revenue forecast at $3,258,129, and the highest APRE revenue forecast at $3,258,129.
In 2026, APRE is forecast to generate $3,258,129 in revenue, with the lowest revenue forecast at $3,258,129 and the highest revenue forecast at $3,258,129.